USS Investment Management Ltd Acquires Shares of 27,850 BioNTech SE (NASDAQ:BNTX)

USS Investment Management Ltd acquired a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 27,850 shares of the company's stock, valued at approximately $3,117,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BNTX. Daiwa Securities Group Inc. increased its stake in shares of BioNTech by 7.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock worth $221,000 after acquiring an additional 128 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of BioNTech by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after purchasing an additional 150 shares during the period. Midwest Professional Planners LTD. grew its holdings in shares of BioNTech by 5.8% in the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock valued at $462,000 after purchasing an additional 222 shares during the period. Perigon Wealth Management LLC increased its position in BioNTech by 3.9% during the fourth quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company's stock worth $666,000 after purchasing an additional 224 shares during the last quarter. Finally, Atomi Financial Group Inc. raised its stake in BioNTech by 6.7% during the fourth quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company's stock worth $414,000 after purchasing an additional 229 shares during the period. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Stock Down 1.0%

Shares of BNTX stock traded down $1.02 during trading on Wednesday, reaching $97.53. The company's stock had a trading volume of 510,716 shares, compared to its average volume of 918,184. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The stock's 50-day moving average price is $97.43 and its 200 day moving average price is $108.31. The company has a market capitalization of $23.45 billion, a price-to-earnings ratio of -46.44 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company's quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.90 earnings per share. On average, research analysts anticipate that BioNTech SE will post -3.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Citigroup reissued a "buy" rating and issued a $140.00 price target (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Canaccord Genuity Group reiterated a "buy" rating and issued a $171.44 price objective on shares of BioNTech in a research report on Tuesday, March 11th. BMO Capital Markets raised their target price on BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and issued a $134.00 price target on shares of BioNTech in a research note on Thursday, May 22nd. Finally, Morgan Stanley lowered their price target on BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $141.73.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.